Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2Br.Mn |
| Molecular Weight | 214.746 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Mn++].[Br-].[Br-]
InChI
InChIKey=RJYMRRJVDRJMJW-UHFFFAOYSA-L
InChI=1S/2BrH.Mn/h2*1H;/q;;+2/p-2
| Molecular Formula | BrH |
| Molecular Weight | 80.912 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Mn |
| Molecular Weight | 54.938045 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/3725729 | https://www.ncbi.nlm.nih.gov/pubmed/3989083 | https://www.ncbi.nlm.nih.gov/pubmed/25464291 | https://www.ncbi.nlm.nih.gov/pubmed/20934746https://www.drugs.com/pro/manganese-sulfate-injection.htmlhttps://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=184 | https://www.ncbi.nlm.nih.gov/pubmed/24861367https://www.alfa.com/en/catalog/032808/https://google.com/patents/CN104529454A?http://www.druginfosys.com/drug.aspx?drugcode=2295&type=1https://www.ncbi.nlm.nih.gov/pubmed/6658791http://pubs.acs.org/doi/pdfplus/10.1021/jo970656jCurator's Comment: description was created based on several sources, including
http://sites.chem.colostate.edu/diverdi/all_courses/CRC%20reference%20data/solubility%20of%20inorganic%20compounds.pdf | https://www.google.com/patents/DE102016209961A1
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3725729 | https://www.ncbi.nlm.nih.gov/pubmed/3989083 | https://www.ncbi.nlm.nih.gov/pubmed/25464291 | https://www.ncbi.nlm.nih.gov/pubmed/20934746https://www.drugs.com/pro/manganese-sulfate-injection.htmlhttps://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=184 | https://www.ncbi.nlm.nih.gov/pubmed/24861367https://www.alfa.com/en/catalog/032808/https://google.com/patents/CN104529454A?http://www.druginfosys.com/drug.aspx?drugcode=2295&type=1https://www.ncbi.nlm.nih.gov/pubmed/6658791http://pubs.acs.org/doi/pdfplus/10.1021/jo970656j
Curator's Comment: description was created based on several sources, including
http://sites.chem.colostate.edu/diverdi/all_courses/CRC%20reference%20data/solubility%20of%20inorganic%20compounds.pdf | https://www.google.com/patents/DE102016209961A1
Manganese Bromide is a highly water soluble crystalline salt composed of manganese and bromine with the formula MnBr2. Manganese Bromide can be used in place of palladium in the Stille reaction, which couples two carbon atoms using an organotin compound
Originator
Sources: https://www.americanelements.com/manganese-ii-iodide-7790-33-2http://www.newworldencyclopedia.org/entry/Manganesehttps://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19610920&CC=GB&NR=877677A&KC=A
Curator's Comment: Manganese was first discovered by Torbern Olof Bergman in 1770 and first isolated by Johann Gottlieb Gahn in 1774.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1075097 |
|||
Target ID: CHEMBL1795148 |
|||
Target ID: CHEMBL4612 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseManganese is used for prevention and treatment of manganese deficiency, a condition in which the body doesn’t have enough manganese. |
|||
| Primary | Unknown Approved UseManganese is used for weak bones (osteoporosis). |
|||
| Palliative | Unknown Approved UseEarly research suggests that taking manganese along with calcium helps improve symptoms of PMS, including pain, crying, loneliness, anxiety, restlessness, irritability, mood swings, depression, and tension. |
|||
| Curative | MANGANESE SULFATE Approved UseManganese Sulfate Injection, USP is indicated for use as a supplement to intravenous solutions given for Total Parenteral Nutrition (TPN). Administration helps to maintain plasma levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. |
|||
| Primary | MANGANESE SULFATE Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Top-Down Strategy to Synthesize Mesoporous Dual Carbon Armored MnO Nanoparticles for Lithium-Ion Battery Anodes. | 2017-04-12 |
|
| Intramolecular Aminoalkoxylation of Unfunctionalized Olefins via Intramolecular Iodoamination and Aziridinium Ion Ring-Opening Sequence. | 2017-04-07 |
|
| Chronic exposure to manganese sulfate leads to adverse dose-dependent effects on the neurobehavioral ability of rats. | 2016-11 |
|
| Yolk-Shell MnO@ZnMn2 O4 /N-C Nanorods Derived from α-MnO2 /ZIF-8 as Anode Materials for Lithium Ion Batteries. | 2016-10 |
|
| Controlled Synthesis of Hollow Manganese Oxide Nanocrystals. | 2016-02 |
|
| Safety Assessment of Citric Acid, Inorganic Citrate Salts, and Alkyl Citrate Esters as Used in Cosmetics. | 2014-05 |
|
| Expression profile analysis of antioxidative stress and developmental pathway genes in the manganese-exposed intertidal copepod Tigriopus japonicus with 6K oligochip. | 2013-08 |
|
| Effects of chronic manganese exposure on glutamatergic and GABAergic neurotransmitter markers in the nonhuman primate brain. | 2009-09 |
|
| Manganese inhalation by rhesus monkeys is associated with brain regional changes in biomarkers of neurotoxicity. | 2007-06 |
|
| CsR(R(6)CoI(12))2 (R = Gd, Er) and (CeI)0.26(Ce(6)MnI(9))2: two new structure types featuring R(6)Z clusters. | 2006-11-27 |
|
| Decreased expression of inflammation-related genes following inhalation exposure to manganese. | 2006-05 |
|
| Alterations of oxidative stress biomarkers due to in utero and neonatal exposures of airborne manganese. | 2006 |
|
| Persistent alterations in biomarkers of oxidative stress resulting from combined in utero and neonatal manganese inhalation. | 2005-05 |
|
| Manganese potentiates in vitro production of proinflammatory cytokines and nitric oxide by microglia through a nuclear factor kappa B-dependent mechanism. | 2005-03 |
|
| Bi- and poly-metallic cyanide-bridged complexes of the redox-active cyanomanganese nitrosyl unit [Mn(CN)(PR3)(NO)(eta-C5H4Me)]. | 2004-02-21 |
|
| Manganese distribution across the blood-brain barrier. I. Evidence for carrier-mediated influx of managanese citrate as well as manganese and manganese transferrin. | 2003-01 |
|
| Glutamate/aspartate transporter (GLAST), taurine transporter and metallothionein mRNA levels are differentially altered in astrocytes exposed to manganese chloride, manganese phosphate or manganese sulfate. | 2002-09 |
|
| Is the axial zero-field splitting parameter of tetragonally elongated high-spin manganese(III) complexes always negative? | 2002-07-31 |
|
| Tetraaqua(1,10-phenanthroline-kappa(2)N,N')manganese(II) sulfate dihydrate. | 2002-07 |
|
| Differential ability of transition metals to induce pulmonary inflammation. | 2001-11-15 |
|
| Equilibrium and kinetics studies of reactions of manganese acetate, cobalt acetate, and bromide salts in acetic acid solutions. | 2001-06-18 |
|
| Manganese citrate chemistry: syntheses, spectroscopic studies, and structural characterizations of novel mononuclear, water-soluble manganese citrate complexes. | 2000-09-04 |
|
| Manganese: brain transport and emerging research needs. | 2000-06 |
|
| Manganese citrate improves base-calling accuracy in DNA sequencing reactions using rhodamine-based fluorescent dye-terminators. | 1999-03-01 |
|
| Transformation of BALB/c-3T3 cells: IV. Rank-ordered potency of 24 chemical responses detected in a sensitive new assay procedure. | 1993-07 |
|
| Dietary calcium and manganese effects on menstrual cycle symptoms. | 1993-05 |
|
| Effect of quantity and route of administration of manganese monoxide on feed intake and serum manganese in ruminants. | 1985-02 |
|
| Effect of fluoride on copper, manganese and zinc in bone and kidney. | 1981-03 |
|
| Metabolism of l-Tyrosine to 4-Hydroxybenzaldehyde and 3-Bromo-4-Hydroxybenzaldehyde by Chloroplast-containing Fractions of Odonthalia floccosa (Esp.) Falk. | 1979-12 |
|
| Cytochrome oxidase determination using a manganese citrate complex. | 1970 |
Patents
Sample Use Guides
Broiler chicks:A basal corn-soybean meal diet (35 ppm Mn) was supplemented with 40, 80, or 120 ppm Mn from Manganese monoxide and fed ad libitum for 21 days.
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: In vitro cytotoxicity of manganese oxide (MnO) using live/dead cell assay, lactate dehydrogenase assay, and reactive oxygen species detection with variation of the concentration of nanoparticles (5-500 ug/ml), incubation time (18-96 h), and different human cell lines (lung adenocarcinoma, breast cancer cells, and glioblastoma cells) was studied. The cytotoxic effect was negligible for 18 h incubation even at highest concentration of 500 ug/ml MnO nanoparticle.
Naked Manganese monoxide (MnO) nanoparticles had the
cytototoxic effect with IC50 value more than 0.1 mg/ml in BRL 3A rat liver cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:27:01 GMT 2025
by
admin
on
Mon Mar 31 19:27:01 GMT 2025
|
| Record UNII |
U70U4T7N6S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000086160
Created by
admin on Mon Mar 31 19:27:01 GMT 2025 , Edited by admin on Mon Mar 31 19:27:01 GMT 2025
|
PRIMARY | |||
|
MANGANESE(II) BROMIDE
Created by
admin on Mon Mar 31 19:27:01 GMT 2025 , Edited by admin on Mon Mar 31 19:27:01 GMT 2025
|
PRIMARY | |||
|
U70U4T7N6S
Created by
admin on Mon Mar 31 19:27:01 GMT 2025 , Edited by admin on Mon Mar 31 19:27:01 GMT 2025
|
PRIMARY | |||
|
SUB03074MIG
Created by
admin on Mon Mar 31 19:27:01 GMT 2025 , Edited by admin on Mon Mar 31 19:27:01 GMT 2025
|
PRIMARY | |||
|
DTXSID2065460
Created by
admin on Mon Mar 31 19:27:01 GMT 2025 , Edited by admin on Mon Mar 31 19:27:01 GMT 2025
|
PRIMARY | |||
|
83471
Created by
admin on Mon Mar 31 19:27:01 GMT 2025 , Edited by admin on Mon Mar 31 19:27:01 GMT 2025
|
PRIMARY | |||
|
m7060
Created by
admin on Mon Mar 31 19:27:01 GMT 2025 , Edited by admin on Mon Mar 31 19:27:01 GMT 2025
|
PRIMARY | Merck Index | ||
|
U70U4T7N6S
Created by
admin on Mon Mar 31 19:27:01 GMT 2025 , Edited by admin on Mon Mar 31 19:27:01 GMT 2025
|
PRIMARY | |||
|
13446-03-2
Created by
admin on Mon Mar 31 19:27:01 GMT 2025 , Edited by admin on Mon Mar 31 19:27:01 GMT 2025
|
PRIMARY | |||
|
236-591-9
Created by
admin on Mon Mar 31 19:27:01 GMT 2025 , Edited by admin on Mon Mar 31 19:27:01 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
SOLVATE->ANHYDROUS |
